Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > This is Much Bigger Than Barium
View:
Post by biggdogg on Dec 20, 2024 12:23pm

This is Much Bigger Than Barium

Big Pharma is about iodine, less about barium, iodine is over $4.5billion/yr, and in great shortages, Iodine is what drives the billion $ revenues for these contrast companies. I think something much bigger is at play, and centers around Voy new technology, the Streamline iodine system. Fullerene is huge too. This is fantastic news.
Comment by biggdogg on Dec 20, 2024 1:01pm
From MD&A Voyageur has designed a proprietary streamlined iodine production system that creates vertical integration of all essential iodine-based compounds used in the creation of iodine contrast drugs. ICI is the starting compound for all iodine components including the intermediary compound 5-amino-2,4,6-triiodoisophthalic dichloride. The Voyageur streamlined method will eliminate the need ...more  
Comment by lscfa on Dec 20, 2024 1:36pm
This disclosure appears for the 1st time in the MD&A dated July 31, 2024. I missed it and probably so did many others because we assumed mgmt was just copy and pasting from one qtr to the next. It should have been disclosed in a news release as a material event. Vertical Integration Strategy - a New Process to Make Iodine Drugs: Voyageur has designed a proprietary streamlined iodine ...more  
Comment by biggdogg on Dec 20, 2024 3:04pm
This is Big Business, which is highly competitive and cutthroat. I think they are playing this smart, the confidentiality around their iodine project has been a major secret so far. The MD&A is well written and explains their master plan. They are moving forward to vertically integrate barium, iodine and eventually carbon drugs. The fact that there is no iodine/barium drug production in the US ...more  
Comment by austrochris1 on Dec 20, 2024 3:24pm
fantastic news for this small company!  
Comment by lscfa on Dec 21, 2024 12:41pm
Rereading the NR it is clear that the co. is talking about iodine contrast and not barium.  The comments are about diversifying product mix, expanding entry into this market, accelerating entry into a segment of the contrast media industry. So maybe the co. focus will be on building a GMP facility to first produce iodine and barium second. The iodine capex is only $7.5M vs $22.5M for ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1